[
 {
  "trial": "T027",
  "source": "fulltext",
  "arms": {
   "Intervention group": {
    "randomized": null,
    "analysed": "67"
   },
   "Control group": {
    "randomized": null,
    "analysed": "67"
   }
  },
  "depression": [
   {
    "measure": "Edinburgh Postnatal Depression Scale (EPDS)",
    "day": -1,
    "form": "mean_sd",
    "location": "Table 2",
    "values": {
     "Intervention group": {
      "mean": "13.78",
      "sd": "3.87",
      "n": null
     },
     "Control group": {
      "mean": "13.79",
      "sd": "4.78",
      "n": null
     }
    }
   },
   {
    "measure": "Edinburgh Postnatal Depression Scale (EPDS)",
    "day": 14,
    "form": "mean_sd",
    "location": "Table 2",
    "values": {
     "Intervention group": {
      "mean": "11.82",
      "sd": "3.41",
      "n": null
     },
     "Control group": {
      "mean": "14.34",
      "sd": "4.29",
      "n": null
     }
    }
   },
   {
    "measure": "Edinburgh Postnatal Depression Scale (EPDS)",
    "day": 28,
    "form": "mean_sd",
    "location": "Table 2",
    "values": {
     "Intervention group": {
      "mean": "10.84",
      "sd": "3.48",
      "n": null
     },
     "Control group": {
      "mean": "13.09",
      "sd": "3.79",
      "n": null
     }
    }
   }
  ],
  "pain": [],
  "adverse_events": [],
  "blinding_check": null,
  "enrollment": null,
  "registration": null,
  "note": "Table 2 labels the arms by drug: 'Ketamine-Nesdonal group' = Intervention group (ketamine 0.5 mg/kg with Nesdonal at induction), 'Nesdonal group' = Control group; the Results text's within-group trends match these columns. Times: 'before caesarian section' = day -1; 'two weeks after' = 14; 'four weeks after' = 28 (EPDS by phone). Results say 'In total, 67 participants were studied in both groups'; Table 1's frequencies with their percentages (for example history of depression Yes 15 (22.4), No 52 (77.6) in the intervention group, Yes 10 (14.9), No 57 (85.1) in the control group) fit 67 in each arm, so 67 is recorded as analysed per arm. No number randomized per arm (sample size planned 35 per group) and no n per time point. The Results text gives mean age 27.4±4.09 for the Nesdonal group and 28.24±4.81 for the Ketamine-Nesdonal group, the reverse of Table 1's Intervention/Control columns; Table 2 names its columns by drug, so the outcomes are unaffected. No adverse events, blinding check, enrollment dates or registration reported."
 },
 {
  "trial": "T037",
  "source": "registry",
  "arms": {
   "Low-Dose Ketamine (LDK) Treatment Group": {
    "randomized": "1",
    "analysed": "0"
   },
   "Control Group": {
    "randomized": "0",
    "analysed": "0"
   }
  },
  "depression": [],
  "pain": [],
  "adverse_events": [
   {
    "window": "overall",
    "time": "registry adverse-event time frame: 1 day",
    "location": "Adverse events (1 day)",
    "values": {
     "Low-Dose Ketamine (LDK) Treatment Group": {
      "any_ae": "0"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": null,
  "registration": {
   "number": "NCT05229653",
   "date": null
  },
  "note": "ClinicalTrials.gov posted results. Participant flow: STARTED 1 (LDK) and 0 (Control); COMPLETED 0 and 0; NOT COMPLETED 1 and 0. 'randomized' records the STARTED counts. Every outcome (MADRS at baseline and POD 1, 27, 55, 83; pelvic pain VAS at the same times; GAD-7; EHP-30; change in opioid use) lists Analysed 0 in both arms and no values, so there are no depression or pain entries. Adverse events (1 day): LDK serious 0/1, other 0/1; Control serious 0/0, other 0/0 (no one at risk, so no control entry). any_ae '0' for LDK rests on 0 serious and 0 other events of 1 at risk."
 },
 {
  "trial": "T046",
  "source": "library",
  "arms": {
   "Placebo group": {
    "randomized": "100",
    "analysed": "97"
   },
   "Low-dose esketamine group (1 mg/kg PCIA)": {
    "randomized": "100",
    "analysed": "99"
   },
   "High-dose esketamine group (2 mg/kg PCIA)": {
    "randomized": "100",
    "analysed": "99"
   }
  },
  "depression": [
   {
    "measure": "EPDS (PDS = EPDS > 9; remission EPDS < 6; total score)",
    "day": -1,
    "form": "median_iqr",
    "location": "Results 3.3, text",
    "values": {
     "Placebo group": {
      "median": "12.0",
      "q1": "11.0",
      "q3": "13.0",
      "n": null
     },
     "Low-dose esketamine group (1 mg/kg PCIA)": {
      "median": "12.0",
      "q1": "10.0",
      "q3": "13.0",
      "n": null
     },
     "High-dose esketamine group (2 mg/kg PCIA)": {
      "median": "11.0",
      "q1": "10.0",
      "q3": "13.0",
      "n": null
     }
    }
   },
   {
    "measure": "EPDS (PDS = EPDS > 9; remission EPDS < 6; total score)",
    "day": 7,
    "form": "count",
    "location": "Table 2",
    "definition": "EPDS > 9 (PDS)",
    "values": {
     "Placebo group": {
      "events": "29",
      "n": "97"
     },
     "Low-dose esketamine group (1 mg/kg PCIA)": {
      "events": "11",
      "n": "99"
     },
     "High-dose esketamine group (2 mg/kg PCIA)": {
      "events": "7",
      "n": "99"
     }
    }
   },
   {
    "measure": "EPDS (PDS = EPDS > 9; remission EPDS < 6; total score)",
    "day": 7,
    "form": "median_iqr",
    "location": "Results 3.3, text (Fig. 2)",
    "values": {
     "Placebo group": {
      "median": "7.0",
      "q1": "4.0",
      "q3": "10.0",
      "n": "97"
     },
     "Low-dose esketamine group (1 mg/kg PCIA)": {
      "median": "5.0",
      "q1": "2.0",
      "q3": "7.0",
      "n": "99"
     },
     "High-dose esketamine group (2 mg/kg PCIA)": {
      "median": "4.0",
      "q1": "1.0",
      "q3": "7.0",
      "n": "99"
     }
    }
   },
   {
    "measure": "EPDS (PDS = EPDS > 9; remission EPDS < 6; total score)",
    "day": 7,
    "form": "change_median_iqr",
    "location": "Results 3.3, text (Fig. 3)",
    "values": {
     "Placebo group": {
      "median": "-5.0",
      "q1": "-9.0",
      "q3": "-2.0",
      "n": "97"
     },
     "Low-dose esketamine group (1 mg/kg PCIA)": {
      "median": "-7.0",
      "q1": "-10.0",
      "q3": "-4.0",
      "n": "99"
     },
     "High-dose esketamine group (2 mg/kg PCIA)": {
      "median": "-8.0",
      "q1": "-10.0",
      "q3": "-5.0",
      "n": "99"
     }
    }
   },
   {
    "measure": "EPDS (PDS = EPDS > 9; remission EPDS < 6; total score)",
    "day": 42,
    "form": "count",
    "location": "Table 2",
    "definition": "EPDS > 9 (PDS)",
    "values": {
     "Placebo group": {
      "events": "27",
      "n": "97"
     },
     "Low-dose esketamine group (1 mg/kg PCIA)": {
      "events": "14",
      "n": "99"
     },
     "High-dose esketamine group (2 mg/kg PCIA)": {
      "events": "9",
      "n": "99"
     }
    }
   },
   {
    "measure": "EPDS (PDS = EPDS > 9; remission EPDS < 6; total score)",
    "day": 42,
    "form": "median_iqr",
    "location": "Results 3.3, text (Fig. 2)",
    "values": {
     "Placebo group": {
      "median": "6.0",
      "q1": "3.0",
      "q3": "10.0",
      "n": "97"
     },
     "Low-dose esketamine group (1 mg/kg PCIA)": {
      "median": "5.0",
      "q1": "2.0",
      "q3": "8.0",
      "n": "99"
     },
     "High-dose esketamine group (2 mg/kg PCIA)": {
      "median": "3.0",
      "q1": "1.0",
      "q3": "7.0",
      "n": "99"
     }
    }
   },
   {
    "measure": "EPDS (PDS = EPDS > 9; remission EPDS < 6; total score)",
    "day": 42,
    "form": "change_median_iqr",
    "location": "Results 3.3, text (Fig. 3)",
    "values": {
     "Placebo group": {
      "median": "-6.0",
      "q1": "-9.0",
      "q3": "-2.5",
      "n": "97"
     },
     "Low-dose esketamine group (1 mg/kg PCIA)": {
      "median": "-7.00",
      "q1": "-10.0",
      "q3": "-4.0",
      "n": "99"
     },
     "High-dose esketamine group (2 mg/kg PCIA)": {
      "median": "-8.0",
      "q1": "-10.0",
      "q3": "-5.0",
      "n": "99"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "NRS postoperative pain",
    "day": 1,
    "form": "median_iqr",
    "location": "Results 3.3, text (at rest, 24 h; Fig. 4a)",
    "values": {
     "Placebo group": {
      "median": "2.0",
      "q1": "2.0",
      "q3": "3.0",
      "n": null
     },
     "Low-dose esketamine group (1 mg/kg PCIA)": {
      "median": "2.0",
      "q1": "1.0",
      "q3": "2.0",
      "n": null
     },
     "High-dose esketamine group (2 mg/kg PCIA)": {
      "median": "2.0",
      "q1": "1.0",
      "q3": "3.0",
      "n": null
     }
    }
   },
   {
    "measure": "NRS postoperative pain",
    "day": 2,
    "form": "median_iqr",
    "location": "Results 3.3, text (at rest, 48 h; Fig. 4a)",
    "values": {
     "Placebo group": {
      "median": "2.0",
      "q1": "2.0",
      "q3": "2.0",
      "n": null
     },
     "Low-dose esketamine group (1 mg/kg PCIA)": {
      "median": "1.0",
      "q1": "1.0",
      "q3": "2.0",
      "n": null
     },
     "High-dose esketamine group (2 mg/kg PCIA)": {
      "median": "1.0",
      "q1": "1.0",
      "q3": "2.0",
      "n": null
     }
    }
   },
   {
    "measure": "NRS score on movement",
    "day": 2,
    "form": "median_iqr",
    "location": "Results 3.3, text (on movement, 48 h; Fig. 4b)",
    "values": {
     "Placebo group": {
      "median": "4.0",
      "q1": "3.0",
      "q3": "5.0",
      "n": null
     },
     "Low-dose esketamine group (1 mg/kg PCIA)": {
      "median": "4.0",
      "q1": "3.0",
      "q3": "4.0",
      "n": null
     },
     "High-dose esketamine group (2 mg/kg PCIA)": {
      "median": "3.0",
      "q1": "3.0",
      "q3": "4.0",
      "n": null
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "intraoperative",
    "location": "Table 3, Intraoperative events",
    "values": {
     "Placebo group": {
      "hallucination": "0",
      "dissociation": "0",
      "visual": "0",
      "dizziness": "2"
     },
     "Low-dose esketamine group (1 mg/kg PCIA)": {
      "hallucination": "2",
      "dissociation": "3",
      "visual": "1",
      "dizziness": "11"
     },
     "High-dose esketamine group (2 mg/kg PCIA)": {
      "hallucination": "1",
      "dissociation": "1",
      "visual": "2",
      "dizziness": "14"
     }
    }
   },
   {
    "window": "postoperative",
    "location": "Table 3, Postoperative events",
    "values": {
     "Placebo group": {
      "dizziness": "3"
     },
     "Low-dose esketamine group (1 mg/kg PCIA)": {
      "dizziness": "4"
     },
     "High-dose esketamine group (2 mg/kg PCIA)": {
      "dizziness": "3"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2020-12",
   "end": "2022-01",
   "location": "Methods 2.1 (study conducted from December 2020 to January 2022); the Results give no dates"
  },
  "registration": {
   "number": "ChiCTR-ROC-2000039069",
   "date": null
  },
  "note": "Columns 'PCIA esketamine 2 mg kg−1' = High-dose, '1 mg kg−1' = Low-dose, 'Placebo'. Randomized 100 per arm (Results 3.1: 300 randomized, 295 completed); analysed 99, 99, 97 (Tables 1–3 column n, abstract). Counts are PDS (EPDS > 9) from Table 2. Table 2 also gives remission (EPDS < 6), not recorded as entries because its events are remissions rather than depression: day 7 placebo 34 (35.1), 1 mg 56 (56.6), 2 mg 68 (68.7); day 42 placebo 39 (40.2), 1 mg 58 (58.6), 2 mg 68 (68.7). EPDS medians (IQR) and median (IQR) changes from baseline (antenatal day 1, recorded as day -1) are from the Results 3.3 text (Figs. 2 and 3 print no values); the n of the medians and of the changes at days 7 and 42 is Table 2's column n (the assessments at those days), the baseline n is not given. Day 7 medians are printed pairwise: placebo 7.0 [4.0, 10.0] vs low dose 5.0 [2.0, 7.0], placebo vs high dose 4.0 [1.0, 7.0]; day 42: high 3.0 [1.0, 7.0] vs placebo 6.0 [3.0, 10.0], high vs low 5.0 [2.0, 8.0]. Minus signs printed as '− ' are written '-'; the low-dose day 42 change is printed '− 7.00'. NRS: at-rest medians printed for 6, 24 and 48 h (6 h is day 0, not recorded; the low-dose 48 h value is printed '1.0 [1.0, 2.0;'); on movement only the 48 h values are printed (24 h: 'no significant differences'), recorded under the source's name. Adverse events from Table 3: nystagmus recorded as visual; intraoperative dysphoria (2 mg 1, 1 mg 1, placebo 0) and muscular hypertonia are not mapped; no postoperative psychotomimetic rows. CADSS was planned at 40 min but only Table 3's dissociation counts are reported. Blinding: the authors state they did not ask participants to guess their group."
 },
 {
  "trial": "T050",
  "source": "fulltext",
  "arms": {
   "Ketamine group": {
    "randomized": null,
    "analysed": "15"
   },
   "Placebo group": {
    "randomized": null,
    "analysed": "15"
   }
  },
  "depression": [
   {
    "measure": "Patient Health Questionnaire-2 (PHQ-2)",
    "day": -1,
    "form": "count",
    "location": "Table 1",
    "definition": "PHQ-2 ≥ 3",
    "values": {
     "Ketamine group": {
      "events": "3",
      "n": "15"
     },
     "Placebo group": {
      "events": "2",
      "n": "15"
     }
    }
   },
   {
    "measure": "Patient Health Questionnaire-2 (PHQ-2)",
    "day": -1,
    "form": "difference",
    "location": "Table 3",
    "estimate": "0",
    "lower": null,
    "upper": null,
    "level": null,
    "scale": "median_difference",
    "comparison": "Ketamine group minus Placebo group (Table 3: Ketamine – Control)",
    "p": "0.75",
    "values": {
     "Ketamine group": {
      "n": null
     },
     "Placebo group": {
      "n": null
     }
    }
   },
   {
    "measure": "Patient Health Questionnaire-2 (PHQ-2)",
    "day": 7,
    "form": "difference",
    "location": "Table 3",
    "estimate": "0",
    "lower": null,
    "upper": null,
    "level": null,
    "scale": "median_difference",
    "comparison": "Ketamine group minus Placebo group (Table 3: Ketamine – Control)",
    "p": "0.96",
    "values": {
     "Ketamine group": {
      "n": null
     },
     "Placebo group": {
      "n": null
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "BPI pain severity subscale",
    "day": 1,
    "form": "difference",
    "location": "Table 3",
    "estimate": "-0.50",
    "lower": null,
    "upper": null,
    "level": null,
    "scale": "median_difference",
    "comparison": "Ketamine group minus Placebo group (Table 3: Ketamine – Control)",
    "p": "0.55",
    "values": {
     "Ketamine group": {
      "n": null
     },
     "Placebo group": {
      "n": null
     }
    }
   },
   {
    "measure": "BPI pain severity subscale",
    "day": 2,
    "form": "difference",
    "location": "Table 3",
    "estimate": "0.25",
    "lower": null,
    "upper": null,
    "level": null,
    "scale": "median_difference",
    "comparison": "Ketamine group minus Placebo group (Table 3: Ketamine – Control)",
    "p": "0.82",
    "values": {
     "Ketamine group": {
      "n": null
     },
     "Placebo group": {
      "n": null
     }
    }
   },
   {
    "measure": "BPI average",
    "day": 1,
    "form": "difference",
    "location": "Table 3",
    "estimate": "0",
    "lower": null,
    "upper": null,
    "level": null,
    "scale": "median_difference",
    "comparison": "Ketamine group minus Placebo group (Table 3: Ketamine – Control)",
    "p": "0.65",
    "values": {
     "Ketamine group": {
      "n": null
     },
     "Placebo group": {
      "n": null
     }
    }
   },
   {
    "measure": "BPI average",
    "day": 2,
    "form": "difference",
    "location": "Table 3",
    "estimate": "0",
    "lower": null,
    "upper": null,
    "level": null,
    "scale": "median_difference",
    "comparison": "Ketamine group minus Placebo group (Table 3: Ketamine – Control)",
    "p": "0.92",
    "values": {
     "Ketamine group": {
      "n": null
     },
     "Placebo group": {
      "n": null
     }
    }
   },
   {
    "measure": "BPI worst",
    "day": 1,
    "form": "difference",
    "location": "Table 3",
    "estimate": "0",
    "lower": null,
    "upper": null,
    "level": null,
    "scale": "median_difference",
    "comparison": "Ketamine group minus Placebo group (Table 3: Ketamine – Control)",
    "p": "0.90",
    "values": {
     "Ketamine group": {
      "n": null
     },
     "Placebo group": {
      "n": null
     }
    }
   },
   {
    "measure": "BPI worst",
    "day": 2,
    "form": "difference",
    "location": "Table 3",
    "estimate": "0",
    "lower": null,
    "upper": null,
    "level": null,
    "scale": "median_difference",
    "comparison": "Ketamine group minus Placebo group (Table 3: Ketamine – Control)",
    "p": "0.90",
    "values": {
     "Ketamine group": {
      "n": null
     },
     "Placebo group": {
      "n": null
     }
    }
   },
   {
    "measure": "BPI least",
    "day": 1,
    "form": "difference",
    "location": "Table 3",
    "estimate": "0",
    "lower": null,
    "upper": null,
    "level": null,
    "scale": "median_difference",
    "comparison": "Ketamine group minus Placebo group (Table 3: Ketamine – Control)",
    "p": "0.61",
    "values": {
     "Ketamine group": {
      "n": null
     },
     "Placebo group": {
      "n": null
     }
    }
   },
   {
    "measure": "BPI least",
    "day": 2,
    "form": "difference",
    "location": "Table 3",
    "estimate": "0",
    "lower": null,
    "upper": null,
    "level": null,
    "scale": "median_difference",
    "comparison": "Ketamine group minus Placebo group (Table 3: Ketamine – Control)",
    "p": "0.97",
    "values": {
     "Ketamine group": {
      "n": null
     },
     "Placebo group": {
      "n": null
     }
    }
   },
   {
    "measure": "BPI current",
    "day": 1,
    "form": "difference",
    "location": "Table 3",
    "estimate": "-1",
    "lower": null,
    "upper": null,
    "level": null,
    "scale": "median_difference",
    "comparison": "Ketamine group minus Placebo group (Table 3: Ketamine – Control)",
    "p": "0.23",
    "values": {
     "Ketamine group": {
      "n": null
     },
     "Placebo group": {
      "n": null
     }
    }
   },
   {
    "measure": "BPI current",
    "day": 2,
    "form": "difference",
    "location": "Table 3",
    "estimate": "-1",
    "lower": null,
    "upper": null,
    "level": null,
    "scale": "median_difference",
    "comparison": "Ketamine group minus Placebo group (Table 3: Ketamine – Control)",
    "p": "0.52",
    "values": {
     "Ketamine group": {
      "n": null
     },
     "Placebo group": {
      "n": null
     }
    }
   },
   {
    "measure": "opioid usage",
    "day": 1,
    "form": "difference",
    "location": "Table 3",
    "estimate": "0",
    "lower": null,
    "upper": null,
    "level": null,
    "scale": "median_difference",
    "comparison": "Ketamine group minus Placebo group (Table 3: Ketamine – Control)",
    "p": "0.83",
    "values": {
     "Ketamine group": {
      "n": null
     },
     "Placebo group": {
      "n": null
     }
    }
   },
   {
    "measure": "opioid usage",
    "day": 2,
    "form": "difference",
    "location": "Table 3",
    "estimate": "0",
    "lower": null,
    "upper": null,
    "level": null,
    "scale": "median_difference",
    "comparison": "Ketamine group minus Placebo group (Table 3: Ketamine – Control)",
    "p": "0.81",
    "values": {
     "Ketamine group": {
      "n": null
     },
     "Placebo group": {
      "n": null
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "postoperative",
    "time": "POD 0, 30 minutes after the infusion (given in the PACU)",
    "location": "Results, text",
    "values": {
     "Ketamine group": {
      "any_ae": "7"
     },
     "Placebo group": {
      "any_ae": "7"
     }
    }
   },
   {
    "window": "postoperative",
    "time": "POD 1",
    "location": "Results, text",
    "values": {
     "Ketamine group": {
      "any_ae": "8"
     },
     "Placebo group": {
      "any_ae": "5"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2021-04",
   "end": "2022-04",
   "location": "Methods (study performed from April 2021 to April 2022); the Results give no dates"
  },
  "registration": {
   "number": "NCT04831736",
   "date": "05/04/2021"
  },
  "note": "Single-blind pilot; ketamine 0.6 mg/kg over about 45 min in the PACU. 31 randomized; 1 withdrawn on the day of surgery before receiving the intervention (arm not stated, CONSORT figure not printed), so randomized per arm is not given; analysed 15 per arm (Table 1 'Ketamine (n=15)', 'Control (n=15)'; Control = Placebo group). Table 3 gives only Wilcoxon median differences (Ketamine – Control) with P values, no arm-level values, for PHQ-2 (baseline, POD 7), BPI (baseline, POD 0, 1, 2, 7) and opioid use (POD 0, 1, 2, 7); minus signs written '-'. 'BPI pain severity subscale' is Table 3's row 'BPI mean' (arithmetic mean of the 4 items); the item rows (average, worst, least, current) are recorded under their own names. POD 1 = 24 h and POD 2 = 48 h (the primary endpoint). Baseline PHQ-2 ≥ 3 counts from Table 1. Side effects: the text spells out 'seven (46.7%) subjects in each group' 30 minutes after the infusion on POD 0, and 'eight (53.3%)' ketamine vs 'five (33.3%)' placebo on POD 1, reporting some side effect; per-symptom counts are only in Figure 3 (no printed values). Blinding: participants guessed their assignment on POD 1, but only 'no statistically significant difference between groups ... (p = 0.07)' is reported, no guesses by arm. BCPQ (POD 7 only) not recorded. Registration date is the 'first posted' date, printed '05/04/2021' (day and month order not stated)."
 },
 {
  "trial": "T061",
  "source": "fulltext",
  "arms": {
   "Group E": {
    "randomized": "79",
    "analysed": "78"
   },
   "Group C": {
    "randomized": "79",
    "analysed": "77"
   }
  },
  "depression": [
   {
    "measure": "HADS depression subscale (HADS-D)",
    "day": -1,
    "form": "median_iqr",
    "location": "Table 1",
    "values": {
     "Group E": {
      "median": "1",
      "q1": "0",
      "q3": "3",
      "n": "78"
     },
     "Group C": {
      "median": "2",
      "q1": "0",
      "q3": "4",
      "n": "77"
     }
    }
   },
   {
    "measure": "HADS depression subscale (HADS-D)",
    "day": 3,
    "form": "median_iqr",
    "location": "Table 2",
    "values": {
     "Group E": {
      "median": "1",
      "q1": "0",
      "q3": "4",
      "n": "78"
     },
     "Group C": {
      "median": "1",
      "q1": "0",
      "q3": "3",
      "n": "77"
     }
    }
   }
  ],
  "pain": [],
  "adverse_events": [
   {
    "window": "postoperative",
    "location": "Table 4",
    "values": {
     "Group E": {
      "nightmare": "2"
     },
     "Group C": {
      "nightmare": "0"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2023-12-31",
   "end": "2024-03-31",
   "location": "Results ('Between December 31, 2023, and March 31, 2024, 169 patients were assessed for eligibility'); the Methods say December 30, 2023 to March 30, 2024"
  },
  "registration": {
   "number": "ChiCTR2400080363",
   "date": null
  },
  "note": "Group E = esketamine 0.3 then 0.15 mg/kg/h from induction, stopped 30 min before the end of surgery; Group C = saline. 158 randomized, 79 per group; 3 excluded for changing to general anesthesia; analysed 78 (E) and 77 (C). HADS-D printed as median (p25, p75), preoperative (day -1) and POD 3. Nightmare (E 2 (2.6%), C 0 (0%)) sits in Table 4 under the heading 'Intraoperative complications', but the Methods list nightmares among postoperative complications and the text names them with the postoperative events, so the window is recorded as postoperative. No pain scores at 24 or 48 h (only intraoperative opioid doses); no other psychotomimetic events reported."
 },
 {
  "trial": "T090",
  "source": "fulltext",
  "arms": {
   "Control group (group C)": {
    "randomized": "30",
    "analysed": null
   },
   "Esketamine group S1": {
    "randomized": "30",
    "analysed": null
   },
   "Esketamine group S2": {
    "randomized": "30",
    "analysed": null
   },
   "Esketamine group S3": {
    "randomized": "30",
    "analysed": null
   }
  },
  "depression": [
   {
    "measure": "HADS depression subscale",
    "day": -1,
    "form": "mean_sd",
    "location": "Table 4, Preoperative",
    "values": {
     "Control group (group C)": {
      "mean": "3.70",
      "sd": "1.57",
      "n": null
     },
     "Esketamine group S1": {
      "mean": "3.23",
      "sd": "1.45",
      "n": null
     },
     "Esketamine group S2": {
      "mean": "3.10",
      "sd": "1.57",
      "n": null
     },
     "Esketamine group S3": {
      "mean": "3.62",
      "sd": "1.32",
      "n": null
     }
    }
   },
   {
    "measure": "HADS depression subscale",
    "day": null,
    "form": "mean_sd",
    "location": "Table 4, rows under 'Postoperativ' (time not stated)",
    "values": {
     "Control group (group C)": {
      "mean": "3.42",
      "sd": "1.30",
      "n": null
     },
     "Esketamine group S1": {
      "mean": "2.75",
      "sd": "1.35",
      "n": null
     },
     "Esketamine group S2": {
      "mean": "3.13",
      "sd": "1.35",
      "n": null
     },
     "Esketamine group S3": {
      "mean": "3.33",
      "sd": "1.33",
      "n": null
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "NRS at rest (3, 6, 12, 24, 48 h)",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 3, 24h (static state)",
    "values": {
     "Control group (group C)": {
      "median": "1",
      "q1": "1",
      "q3": "1.25",
      "n": null
     },
     "Esketamine group S1": {
      "median": "1",
      "q1": "1",
      "q3": "2",
      "n": null
     },
     "Esketamine group S2": {
      "median": "0",
      "q1": "0",
      "q3": "1",
      "n": null
     },
     "Esketamine group S3": {
      "median": "0",
      "q1": "0",
      "q3": "1",
      "n": null
     }
    }
   },
   {
    "measure": "NRS at rest (3, 6, 12, 24, 48 h)",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 3, 48h (static state)",
    "values": {
     "Control group (group C)": {
      "median": "1",
      "q1": "0",
      "q3": "1",
      "n": null
     },
     "Esketamine group S1": {
      "median": "1",
      "q1": "1",
      "q3": "1",
      "n": null
     },
     "Esketamine group S2": {
      "median": "0",
      "q1": "0",
      "q3": "1",
      "n": null
     },
     "Esketamine group S3": {
      "median": "0",
      "q1": "0",
      "q3": "1",
      "n": null
     }
    }
   },
   {
    "measure": "NRS during exercise (3, 6, 12, 24, 48 h)",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 2, 24h (exercise status)",
    "values": {
     "Control group (group C)": {
      "median": "2",
      "q1": "2",
      "q3": "2",
      "n": null
     },
     "Esketamine group S1": {
      "median": "2",
      "q1": "1",
      "q3": "2",
      "n": null
     },
     "Esketamine group S2": {
      "median": "1",
      "q1": "1",
      "q3": "2",
      "n": null
     },
     "Esketamine group S3": {
      "median": "1",
      "q1": "1",
      "q3": "1",
      "n": null
     }
    }
   },
   {
    "measure": "NRS during exercise (3, 6, 12, 24, 48 h)",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 2, 48h (exercise status)",
    "values": {
     "Control group (group C)": {
      "median": "1",
      "q1": "1",
      "q3": "2",
      "n": null
     },
     "Esketamine group S1": {
      "median": "1",
      "q1": "1",
      "q3": "2",
      "n": null
     },
     "Esketamine group S2": {
      "median": "0",
      "q1": "0",
      "q3": "1",
      "n": null
     },
     "Esketamine group S3": {
      "median": "0",
      "q1": "0",
      "q3": "1",
      "n": null
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "postoperative",
    "location": "Table 9",
    "values": {
     "Control group (group C)": {
      "dizziness": "5",
      "visual": "0"
     },
     "Esketamine group S1": {
      "dizziness": "4",
      "visual": "0"
     },
     "Esketamine group S2": {
      "dizziness": "2",
      "visual": "0"
     },
     "Esketamine group S3": {
      "dizziness": "3",
      "visual": "0"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2023-03",
   "end": "2024-03",
   "location": "Methods (patients included between March 2023 and March 2024); the Results give no dates"
  },
  "registration": {
   "number": "ChiCTR2400090449",
   "date": null
  },
  "note": "Esketamine at induction 0.15 (S1), 0.25 (S2), 0.35 (S3) mg/kg, given until 30 min before the end of surgery; group C saline. 120 randomized, 30 per group. No analysed numbers are stated; the tables' rows print 29 for S2 (for example Table 9 'Diplopia No 30(100), 30(100), 29(100), 30(100)' for C, S1, S2, S3). HADS-D (printed 'HDAS-D' in Table 4): preoperative = day -1; the postoperative assessment time is not stated anywhere, so its day is null. NRS printed as median(Q1,Q3) without n; Table 2 'exercise status' = during exercise, Table 3 'static state' = at rest; 3, 6 and 12 h values not recorded. Sufentanil usage (Table 8: C 37.30 ± 1.58, S1 36.90 ± 2.33, S2 27.48 ± 1.88, S3 21.73 ± 1.82 µg) has no stated time (sufentanil was given intermittently during maintenance) and remedial analgesia (Table 9 yes: 10(33.3), 8(26.7), 6(20.7), 0(0)) covers an unstated postoperative period, so neither is recorded at day 1 or 2. Adverse events, Table 9: 'Dizzy giddy' yes = dizziness; diplopia recorded as visual 0 because its 'No' row is 100% in every group; the nightmare row is printed 'Nightmare yes 30(100) 30(100) 29(100) 30(100)', apparently a mislabelled 'No' row, so nightmares are not recorded. Single-blind; no blinding check."
 },
 {
  "trial": "T099",
  "source": "fulltext",
  "arms": {
   "Esketamine group": {
    "randomized": "102",
    "analysed": "102"
   },
   "Saline group": {
    "randomized": "102",
    "analysed": "102"
   }
  },
  "depression": [
   {
    "measure": "HADS-D",
    "day": -1,
    "form": "median_iqr",
    "location": "Table 1",
    "values": {
     "Esketamine group": {
      "median": "3",
      "q1": "2",
      "q3": "3",
      "n": "102"
     },
     "Saline group": {
      "median": "3",
      "q1": "2",
      "q3": "3",
      "n": "102"
     }
    }
   },
   {
    "measure": "HADS-D",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 3",
    "values": {
     "Esketamine group": {
      "median": "3",
      "q1": "2",
      "q3": "3",
      "n": "102"
     },
     "Saline group": {
      "median": "3",
      "q1": "2",
      "q3": "3",
      "n": "102"
     }
    }
   },
   {
    "measure": "HADS-D",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 3",
    "values": {
     "Esketamine group": {
      "median": "3",
      "q1": "2",
      "q3": "3",
      "n": "102"
     },
     "Saline group": {
      "median": "2.5",
      "q1": "2",
      "q3": "3",
      "n": "102"
     }
    }
   },
   {
    "measure": "HADS-D",
    "day": 3,
    "form": "median_iqr",
    "location": "Table 3",
    "values": {
     "Esketamine group": {
      "median": "3",
      "q1": "2",
      "q3": "3",
      "n": "102"
     },
     "Saline group": {
      "median": "3",
      "q1": "2",
      "q3": "3",
      "n": "102"
     }
    }
   },
   {
    "measure": "HADS-D",
    "day": 7,
    "form": "median_iqr",
    "location": "Table 3",
    "values": {
     "Esketamine group": {
      "median": "3",
      "q1": "2",
      "q3": "3",
      "n": "101"
     },
     "Saline group": {
      "median": "3",
      "q1": "2",
      "q3": "3",
      "n": "100"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "NRS at rest",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 3",
    "values": {
     "Esketamine group": {
      "median": "3",
      "q1": "2",
      "q3": "4",
      "n": "102"
     },
     "Saline group": {
      "median": "4",
      "q1": "3",
      "q3": "4",
      "n": "102"
     }
    }
   },
   {
    "measure": "NRS at rest",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 3",
    "values": {
     "Esketamine group": {
      "median": "2",
      "q1": "2",
      "q3": "3",
      "n": "102"
     },
     "Saline group": {
      "median": "3",
      "q1": "2",
      "q3": "3",
      "n": "102"
     }
    }
   },
   {
    "measure": "NRS after movement",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 3",
    "values": {
     "Esketamine group": {
      "median": "3",
      "q1": "3",
      "q3": "4",
      "n": "102"
     },
     "Saline group": {
      "median": "4",
      "q1": "3",
      "q3": "4",
      "n": "102"
     }
    }
   },
   {
    "measure": "NRS after movement",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 3",
    "values": {
     "Esketamine group": {
      "median": "2",
      "q1": "1",
      "q3": "3",
      "n": "102"
     },
     "Saline group": {
      "median": "3",
      "q1": "2",
      "q3": "3",
      "n": "102"
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "postoperative",
    "time": "within 1 h after surgery",
    "location": "Table 4",
    "values": {
     "Esketamine group": {
      "dizziness": "25",
      "agitation": "2",
      "hallucination": "0",
      "visual": "0"
     },
     "Saline group": {
      "dizziness": "19",
      "agitation": "0",
      "hallucination": "0",
      "visual": "0"
     }
    }
   },
   {
    "window": "postoperative",
    "time": "1–24 h after surgery",
    "location": "Table 4",
    "values": {
     "Esketamine group": {
      "dizziness": "14",
      "agitation": "0",
      "hallucination": "0",
      "visual": "0"
     },
     "Saline group": {
      "dizziness": "11",
      "agitation": "0",
      "hallucination": "0",
      "visual": "0"
     }
    }
   },
   {
    "window": "postoperative",
    "time": "24–72 h after surgery",
    "location": "Table 4",
    "values": {
     "Esketamine group": {
      "dizziness": "9",
      "agitation": "0",
      "hallucination": "0",
      "visual": "0"
     },
     "Saline group": {
      "dizziness": "6",
      "agitation": "0",
      "hallucination": "0",
      "visual": "0"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2024-05-05",
   "end": "2024-10-31",
   "location": "Methods ('Dates of first and last enrollments were May 5, 2024, and October 31, 2024'); the Results give no dates"
  },
  "registration": {
   "number": "NCT06388824",
   "date": null
  },
  "note": "The source calls the saline arm 'Placebo group' (= design 'Saline group'). Esketamine 0.2 mg/kg once, immediately after the start of surgery. 204 randomized, 102 per group; ITT analysis of all 204; 3 declined the day-7 follow-up (per-protocol n = 100 placebo, 101 esketamine). Table 3 marks day-7 values '(2)' (placebo) and '(1)' (esketamine), patients missing owing to refused assessment, so the day-7 n is the per-protocol n printed in Table 3; other n are the column n (102). HADS-D and NRS are median (IQR); Hodges–Lehmann median differences are also printed (HADS-D 0 (0 to 0) at each day). NRS at postoperative hour 1 and days 3 and 7 not recorded. Acetaminophen use over the first three postoperative days (placebo 13 (12.8), esketamine 6 (5.9)) is not a day 1 or 2 value, so not recorded. Adverse events, Table 4 'Postoperative period': delirium within 1 h after surgery placebo 1 (1.0), esketamine 4 (3.9), and 0 in both arms at 1–24 h and 24–72 h, is listed separately from agitation and not added to it; somnolence and memory impairment not mapped; no psychotomimetic rows in the intraoperative period. Text: no serious side effects."
 },
 {
  "trial": "T100",
  "source": "fulltext",
  "arms": {
   "Esketamine group (PE)": {
    "randomized": "66",
    "analysed": "58"
   },
   "Control group (C)": {
    "randomized": "66",
    "analysed": "58"
   }
  },
  "depression": [
   {
    "measure": "HADS depression score",
    "day": 1,
    "form": "difference",
    "location": "Discussion, second paragraph",
    "estimate": "1.5",
    "lower": null,
    "upper": null,
    "level": null,
    "scale": null,
    "comparison": "Control group (C) minus Esketamine group (PE): 'HADS-D scores were 1.5 points lower in group PE'",
    "p": "< 0.05",
    "values": {
     "Esketamine group (PE)": {
      "n": "58"
     },
     "Control group (C)": {
      "n": "58"
     }
    }
   },
   {
    "measure": "HADS depression score",
    "day": 3,
    "form": "difference",
    "location": "Discussion, second paragraph",
    "estimate": "1.5",
    "lower": null,
    "upper": null,
    "level": null,
    "scale": null,
    "comparison": "Control group (C) minus Esketamine group (PE): 'HADS-D scores were 1.5 points lower in group PE'",
    "p": "< 0.05",
    "values": {
     "Esketamine group (PE)": {
      "n": "58"
     },
     "Control group (C)": {
      "n": "58"
     }
    }
   }
  ],
  "pain": [],
  "adverse_events": [
   {
    "window": "postoperative",
    "location": "Results, text ('no patients in either group developed headache, blurred vision, delirium, or block-related complications')",
    "values": {
     "Esketamine group (PE)": {
      "visual": "0"
     },
     "Control group (C)": {
      "visual": "0"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2023-09",
   "end": "2024-02",
   "location": "Methods (patients scheduled between September 2023 and February 2024 were included); the Results give no dates"
  },
  "registration": {
   "number": "ChiCTR2300075055",
   "date": "2023-08-23"
  },
  "note": "The source's tables (Tables 1–7, including Table 3 HADS scores, Table 5 VAS and Table 7 complications) are not reproduced in the text ('Download CSV Display Table') and Figures 2–3 print no values, so no arm-level HADS-D or VAS values could be extracted. Results text: HADS-D lower in group PE on postoperative days 1 and 3 (p < 0.05), no difference preoperatively or on day 7 (p > 0.05). The only number is the Discussion's 'Compared with group C, HADS-D scores were 1.5 points lower in group PE', given once for days 1 and 3 together; it is recorded for both days, but it is unclear whether it applies to each day and whether it is a difference of means or medians (scale null, no CI). 132 randomized (66 per group), 16 dropped out, 116 analysed with complete data; n = 58 per group in the notes to Figures 2 and 3. Group C is the 'placebo group'. Esketamine 0.5 mg/kg at induction plus 1 mg/kg in a 48 h PCIA. Adverse events: Table 7 counts (shivering, fever, nausea and vomiting, abdominal distension, postoperative agitation, hallucinations, dizziness, hypoxemia) are not available; the text says no patient in either group had headache, blurred vision (recorded as visual 0) or delirium. RASS after extubation: no values. Registration date printed 'August 23, 2023'."
 },
 {
  "trial": "T120",
  "source": "fulltext",
  "arms": {
   "Esketamine group": {
    "randomized": "168",
    "analysed": "164"
   },
   "Control group": {
    "randomized": "168",
    "analysed": "158"
   }
  },
  "depression": [
   {
    "measure": "EPDS",
    "day": -1,
    "form": "median_iqr",
    "location": "Table 1",
    "values": {
     "Esketamine group": {
      "median": "6",
      "q1": "4",
      "q3": "7",
      "n": "164"
     },
     "Control group": {
      "median": "5",
      "q1": "3",
      "q3": "8",
      "n": "158"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 7,
    "form": "count",
    "location": "Table 2",
    "definition": "EPDS ≥ 10 (PPD)",
    "values": {
     "Esketamine group": {
      "events": "8",
      "n": "164"
     },
     "Control group": {
      "events": "24",
      "n": "158"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 7,
    "form": "median_iqr",
    "location": "Table 2",
    "values": {
     "Esketamine group": {
      "median": "4",
      "q1": "2",
      "q3": "6",
      "n": "164"
     },
     "Control group": {
      "median": "5",
      "q1": "2",
      "q3": "8",
      "n": "158"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 30,
    "form": "count",
    "location": "Table 2",
    "definition": "EPDS ≥ 10 (PPD)",
    "values": {
     "Esketamine group": {
      "events": "13",
      "n": "158"
     },
     "Control group": {
      "events": "16",
      "n": "149"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 30,
    "form": "median_iqr",
    "location": "Table 2",
    "values": {
     "Esketamine group": {
      "median": "4",
      "q1": "2",
      "q3": "7",
      "n": "158"
     },
     "Control group": {
      "median": null,
      "q1": "2",
      "q3": "7",
      "n": "149"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 60,
    "form": "count",
    "location": "Table 2",
    "definition": "EPDS ≥ 10 (PPD)",
    "values": {
     "Esketamine group": {
      "events": "8",
      "n": "149"
     },
     "Control group": {
      "events": "13",
      "n": "145"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 60,
    "form": "median_iqr",
    "location": "Table 2",
    "values": {
     "Esketamine group": {
      "median": "4",
      "q1": "2",
      "q3": "7",
      "n": "149"
     },
     "Control group": {
      "median": "4",
      "q1": "2",
      "q3": "7",
      "n": "145"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 90,
    "form": "count",
    "location": "Table 2",
    "definition": "EPDS ≥ 10 (PPD)",
    "values": {
     "Esketamine group": {
      "events": "7",
      "n": "146"
     },
     "Control group": {
      "events": "10",
      "n": "143"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 90,
    "form": "median_iqr",
    "location": "Table 2",
    "values": {
     "Esketamine group": {
      "median": "3",
      "q1": "2",
      "q3": "5",
      "n": "146"
     },
     "Control group": {
      "median": "4",
      "q1": "2",
      "q3": "7",
      "n": "143"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "NRS at rest",
    "day": 1,
    "form": "median_iqr",
    "location": "Results, text (24 h; Fig. 3a)",
    "values": {
     "Esketamine group": {
      "median": "2",
      "q1": "1",
      "q3": "4",
      "n": null
     },
     "Control group": {
      "median": "2",
      "q1": "1",
      "q3": "5",
      "n": null
     }
    }
   },
   {
    "measure": "effective PCIA presses",
    "day": 1,
    "form": "median_iqr",
    "location": "Results, text (cumulative over the 24 h PCIA; Fig. 3b)",
    "values": {
     "Esketamine group": {
      "median": "6",
      "q1": "3",
      "q3": "10",
      "n": null
     },
     "Control group": {
      "median": "7",
      "q1": "3.5",
      "q3": "11",
      "n": null
     }
    }
   },
   {
    "measure": "sufentanil consumption",
    "day": 1,
    "form": "median_iqr",
    "location": "Results, text (cumulative 24 h, μg, medians only; Fig. 3c)",
    "values": {
     "Esketamine group": {
      "median": "60",
      "q1": null,
      "q3": null,
      "n": null
     },
     "Control group": {
      "median": "62",
      "q1": null,
      "q3": null,
      "n": null
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "intraoperative",
    "time": "within 1 h after drug administration (during caesarean section)",
    "location": "Table 3",
    "values": {
     "Esketamine group": {
      "dizziness": "18",
      "hallucination": "17",
      "visual": "3",
      "dissociation": "9"
     },
     "Control group": {
      "dizziness": "0",
      "hallucination": "0",
      "visual": "0",
      "dissociation": "0"
     }
    }
   },
   {
    "window": "postoperative",
    "time": "24 h postpartum",
    "location": "Table 3; hallucination and dissociation from the Results text",
    "values": {
     "Esketamine group": {
      "dizziness": "21",
      "visual": "1",
      "hallucination": "0",
      "dissociation": "0"
     },
     "Control group": {
      "dizziness": "9",
      "visual": "0",
      "hallucination": "0",
      "dissociation": "0"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2021-05-01",
   "end": "2024-03-31",
   "location": "Methods (trial conducted from 1 May 2021 to 31 March 2024, which includes the 3-month follow-up); the Results give no dates"
  },
  "registration": {
   "number": "NCT04860661",
   "date": "2021-04-20"
  },
  "note": "Esketamine 0.25 mg/kg 15 min after cord clamping plus 80 mg in the 24 h PCIA; control saline. 336 randomized, 168 per group; modified ITT 164 (esketamine: 1 converted to general anaesthesia, 3 lost) and 158 (control: 4 converted, 6 lost). PPD = EPDS ≥ 10, Table 2 n/total per time. Table 2's EPDS-score rows print no n; their n is taken from the PPD row at the same time. The control median at 1 month is missing in print ('[2 to 7]' only), so it is null. 7 days, 1, 2 and 3 months = days 7, 30, 60, 90. Also printed without counts: total PPD within 3 months 11.59% vs 20.89% (adjusted RR 0.57, 95% CI 0.35 to 0.94). NRS at 2, 6 and 12 h not recorded; the 18 h value (2 [1 to 4] vs 2 [1 to 4]) not recorded because the 24 h value is printed. PCIA presses and sufentanil are cumulative over the 24 h PCIA; sufentanil printed as medians only (60 vs 62 μg). Adverse events, Table 3: the events within 1 h after drug administration occurred during the caesarean ('vanished before the end of surgery'), recorded as intraoperative; nystagmus and diplopia recorded as visual. Hallucinations were euphoric 12, unpleasant 3, neutral 2. Postoperative hallucination and dissociation zeros come from 'No patients experienced hallucination or dissociation after surgery.' Dizziness at 24 h by grade: I 19 vs 9, II 1 vs 0, III 1 vs 0."
 }
]